ライフサイエンスコーパス: thyroxine

1 infant thyroid-stimulating hormone and free thyroxine.

2 mide derivatives of thyroxine or deiodinated thyroxine.

3 ormation of impurities in thermally stressed thyroxine.

4 ring the biosynthesis of the thyroid hormone thyroxine.

5 ssociated with both free thyroxine and total thyroxine.

6 total antioxidant power was not affected by thyroxine.

7 the two binding sites for the natural ligand thyroxine.

8 y measurements of serum thyrotropin and free thyroxine.

9 vasopressin and either triiodothyronine or L-thyroxine.

10 vasopressin and either triiodothyronine or l-thyroxine.

11 ve became hypothyroid and required long-term thyroxine.

12 ocesses could be inhibited by probucol and L-thyroxine.

13 cytes, with triiodothyronine (100 pmol/L) or thyroxine (100 nmol/L).

14 ne, tetramethylrosamine, fluoride, dopamine, thyroxine, 2,4-dinitrotoluene) and activated gene expres

15 Thyroid stimulating hormone, free thyroxine, 25-hydroxy vitamin D3, active smoking status

16 tly increased uptake of triiodothyronine and thyroxine (4.1- and 4.3-fold, respectively), which was a

17 much longer half-life of D3 (12 h) than the thyroxine activating members of the selenodeiodinase fam

18 ated reduction of the type 2 deiodinase, the thyroxine-activating enzyme, and both effects are revers

19 s alone and steroids plus triiodothyronine/l-thyroxine also significantly reduced prolonged graft dys

20 mong these women, associations between total thyroxine and concurrent 1996 TCDD were slightly weaker

21 h hyperthyroidism are low TSH, elevated free-thyroxine and free-triiodothyronine levels, and TSH-rece

22 y that resulted in low circulating levels of thyroxine and IGF-1.

23 tube recognition complexes for riboflavin, L-thyroxine and oestradiol.

24 vidence that transthyretin, a transporter of thyroxine and retinol, is aggregated in preeclampsia and

25 nvolved in the transportation of the hormone thyroxine and retinol-binding protein, in the myocardium

26 blood and cerebrospinal fluid transporter of thyroxine and retinol.

27 , one of which defines the binding sites for thyroxine and small-molecule amyloidogenesis inhibitors.

28 The concentration of thyroxine and the free thyroxine index were higher in th

29 rameric protein involved in the transport of thyroxine and the vitamin A-retinol-binding protein comp

30 nction in mice, resulting in increased serum thyroxine and thyroidal radioiodide uptake.

31 ns were negatively associated with both free thyroxine and total thyroxine.

32 antly associated with greater total and free thyroxine and total triiodothyronine among women and wit

33 pacity for rapid inactivation of circulating thyroxine and triiodothyronine in patients with hemangio

34 stem tone, and circulating concentrations of thyroxine and triiodothyronine returned to pre-weight-lo

35 hormone thyrotropin and the thyroid hormones thyroxine and triiodothyronine) are sometimes used as in

36 on, including those for the thyroid hormones thyroxine and triiodothyronine, are among the clinical p

37 t serum protein responsible for transporting thyroxine and vitamin A.

38 TSH (thyroid-stimulating hormone), FT4 (free thyroxine) and gait, without known thyroid disease or de

39 ) for statins, 1.40 (95% CI: 1.02, 1.92) for thyroxine, and 1.53 (95% CI: 1.04, 2.24) for insulin.

40 One group of HLE B-3 cells was treated with thyroxine, and another group was not.

41 s well as thyroid-stimulating hormone, total thyroxine, and free thyroxine, were measured in serum sa

42 centrations of plasma tri-iodothyronine, low thyroxine, and normal range or slightly decreased concen

43 10 case-control pairs were assessed for free thyroxine, and sera of 948 case-control pairs were asses

44 ating hormone, thyroglobulin, total and free thyroxine, and total and free triiodothyronine.

45 ne and circulating concentrations of leptin, thyroxine, and triiodothyronine act coordinately to favo

46 a on the adverse effects of broader use of L-thyroxine are sparse.

47 vels of transthyretin, a carrier protein for thyroxine, are elevated.

48 This approach was tested using L-thyroxine as a model analyte.

49 that the TTR amyloid is incapable of binding thyroxine as monitored by either isothermal calorimetry

50 e stable isotopic thyroid hormone (13)C(6)-L-thyroxine as the label of which the binding to rTTR is i

51 s, resulting in the formation of deiodinated thyroxines, as well as acetic acid, benzoic acid, formal

52 in (Tg) T cell epitope p2549-2560 containing thyroxine at position 2553 (T4p2553) induces thyroiditis

53 ted six promoters, CMV, EF1alpha, PGK, apoE, thyroxine binding globulin (TBG), and cytochrome P450 2E

54 coagulation factor V, adiponectin, CRP, and thyroxine binding globulin, respectively.

55 coagulation factor V, adiponectin, CRP, and thyroxine binding globulin, respectively.

56 , adiponectin, C-reactive protein (CRP), and thyroxine binding globulin.

57 tion in vitro via an interaction between the thyroxine binding pocket of the TTR tetramer and Abeta r

58 minophenyl substructure to bind to the inner thyroxine binding pocket of TTR.

59 t only utilizes the outer portion of the two thyroxine binding pockets to bind to and inhibit TTR amy

60 he homotetrameric TTR contains two identical thyroxine binding pockets, occupation of which by specif

61 o complement the unused inner portion of the thyroxine binding pockets.

62 units whose quaternary interface defines the thyroxine binding site also dramatically increases the b

63 Binding of small molecule ligands within the thyroxine binding site of TTR can stabilize the tetramer

64 ivity enables these inhibitors to occupy the thyroxine binding site(s) in a complex biological fluid

65 When bound in the thyroxine binding site, most of the aryl sulfonyl fluori

66 teract, albeit weakly, with the preferential thyroxine binding site.

67 ter than the hydrolysis reaction outside the thyroxine binding site.

68 Occupancy of only one of the two thyroxine binding sites is sufficient to inhibit tetrame

69 Although revealing the ability of the two thyroxine binding sites of TTR to discriminate between d

70 tion state by small molecule binding to both thyroxine binding sites raises the kinetic barrier of te

71 of TTR by specifically interacting with its thyroxine binding sites.

72 yl known to have high affinity for the inner thyroxine binding subsite of transthyretin (TTR) was con

73 injecting adeno-associated virus containing thyroxine-binding globulin promoter-driven causes recomb

74 were injected with adeno-associated virus 8-thyroxine-binding globulin-Cre-recombinase versus contro

75 and ~200 nM) to the two normally unoccupied thyroxine-binding sites of the tetramer, and kinetically

76 to deliver Tg to its site of iodination for thyroxine biosynthesis.

77 ghly preferential binding of resveratrol and thyroxine, both characterized by negative binding cooper

78 the relationship between 1976 TCDD and total thyroxine but drove the association with 1996 TCDD to th

79 evel of the predominant thyroid hormone free thyroxine, but not the minimal isoform of triiodothyroni

80 sruption due to high affinity-binding to the thyroxine-carrying protein, transthyretin.

81 xinemia, characterized by low levels of free thyroxine coexisting with reference thyrotropin levels,

82 % CI: 0.12, 1.51) increase in maternal total thyroxine concentrations (TT4), respectively.

83 o decreased circulating triiodothyronine and thyroxine concentrations secondary to reduced mRNA expre

84 evel of 5.0 to 19.96 mIU/l with normal total thyroxine concentrations.

85 id not affect blood lymphocyte or serum free thyroxine concentrations.

86 ngeners were negatively associated with free thyroxine concentrations.

87 18-30 microM included L-thyroxine (L-T4), D-thyroxine (D-T4), 3,3', 5,5'-tetraiodothyroacetic acid (

88 lpha), collagen I and III transcription, and thyroxine decreased cyclin-dependent kinase inhibitor 2A

89 ipation, which improved after treatment with thyroxine, despite normal concentrations of circulating

90 h SCH and high symptom burden at baseline, L-thyroxine did not improve hypothyroid symptoms or tiredn

91 L-thyroxine does not improve hypothyroid symptoms among ad

92 ough it is reasonable to expect a need for a thyroxine dose increase with some antiepileptic drugs, t

93 A continuous infusion of 4 mug/kg per day thyroxine for 42 days can safely correct transient hypot

94 injected either with growth hormone (GH) or thyroxine for a 6-wk period to see whether this interven

95 Thyroxine, free thyroxine index, and thyroid-stimulating

96 981) and 1996 (n = 260), and levels of total thyroxine, free thyroxine, free triiodothyronine, and th

97 = 260), and levels of total thyroxine, free thyroxine, free triiodothyronine, and thyroid-stimulatin

98 otal thyroxine, total triiodothyronine, free thyroxine, free triiodothyronine, parathyroid hormone, p

99 peech), biochemical (subnormal ratio of free thyroxine:free tri-iodothyronine [T3], low concentration

100 ethylhexyldiphenyl phosphate (EHDP) and free thyroxine (FT(4)), between BDE-100 and free triiodothyro

101 In nonhyperthyroid cats, serum free thyroxine (fT(4)), total T(4) (TT(4)), total triiodothyr

102 0.70; 95% CI: -1.06, -0.34], decreasing free thyroxine (fT4) (beta = -0.053; 95% CI: -0.092, -0.013),

103 ne, or TSH) level with normal levels of free thyroxine (FT4) affects up to 10% of the adult populatio

104 cted thyroid stimulating hormone (TSH), free thyroxine (FT4) and thyroid peroxidase antibody (TPOAb)

105 and where free triiodothyronine (fT3), free thyroxine (fT4) and thyroid stimulating hormone (TSH) wa

106 tside the reference range and levels of free thyroxine (FT4) and triiodothyronine (T3) within the ref

107 H using Cox regression and outcomes and free thyroxine (FT4) concentration using restricted cubic-spl

108 l thyroid-stimulating hormone (TSH) and free thyroxine (fT4) levels with plasma concentrations of six

109 hyroidism as TSH 4.5 to 19.9 mIU/L with free thyroxine (fT4) levels within reference range.

110 ars with thyroid-stimulating hormone or free thyroxine (FT4) measurements and clinical follow-up were

111 s of thyroid-stimulating hormone (TSH), free thyroxine (FT4), and thyroglobulin, vary widely due to v

112 oncentrations of triiodothyronine (T3), free thyroxine (FT4), thyroid peroxidase antibody (Anti-TPO),

113 Maternal serum levels of free thyroxine (FT4), thyroid-stimulating hormone (TSH), and

114 le thyroid traits thyrotropin (TSH) and free thyroxine (FT4), we analyse whole-genome sequence data f

115 TCEP had additional overall effects on free thyroxine (FT4), whereas TDCIPP also influenced total th

116 lso positively associated with maternal free thyroxine (FT4).

117 id-stimulating hormone (TSH), free and total thyroxine (fT4, TT4) and triiodothyronine (fT3, TT3), an

118 unction tests (serum thyrotropin [TSH], free thyroxine [fT4], and thyroid peroxidase [TPO] antibodies

119 by solid phase synthesis with immobilised L-thyroxine, glucosamine, fumonisin B2 or biotin as templa

120 ithin the ER with no detectable synthesis of thyroxine, had persistent exposure of free cysteine thio

121 thyroid-stimulating hormone; treatment with thyroxine has been initiated in one patient.

122 growth factor, insulin-like growth factor-1, thyroxine, hepatocyte growth factor, and bone morphogene

123 s (CTL) and hypothyroid rats replaced with L-thyroxine (HT+T).

124 Replacement treatment exists in the form of thyroxine, hydrocortisone, sex steroids, growth hormone,

125 TTR is a tetrameric carrier of thyroxine in blood and cerebrospinal fluid, the pathogen

126 ransthyretin is a transporter of retinol and thyroxine in blood, cerebrospinal fluid, and the eye, an

127 tly shown to reduce levels of free and total thyroxine in experimental animal studies, the direction

128 antiepileptic drugs, the effect of excessive thyroxine in lowering seizure threshold should also be c

129 converting enzyme (ACE), and measuring serum thyroxine in mice given anti-TGFbeta1 or the ACE inhibit

130 hods when used for the determination of free thyroxine in serum samples.

131 e was derived for the thermal degradation of thyroxine in the solid state, using data obtained from u

132 ses for 3 medications (statins, insulin, and thyroxine) in relation to 3 outcomes (retinal detachment

133 i-iodothyronine uptake (T3 uptake), and free thyroxine index (FTI) were measured.

134 ine, triiodothyronine resin uptake, and free thyroxine index (FTI), were determined before initiation

135 The concentration of thyroxine and the free thyroxine index were higher in the ISP56 group, and the

136 Thyroxine, free thyroxine index, and thyroid-stimulating hormone at 6 mo

137 Therefore, thyroxine-induced fluctuations in antioxidant levels are

138 However, binding of RBP, but not thyroxine, inhibited subsequent fibrillogenesis.

139 reased levels of free triiodothyronine, free thyroxine, insulin-like growth factor 1, insulin-like gr

140 Originating in the thyroid, the prohormone thyroxine is converted to triiodothyronine, which is ess

141 Oral L-thyroxine is the treatment of choice because of its well

142 L-thyroxine (L-T4) malabsorption is a potential concern in

143 ith IC(50) values of 18-30 microM included L-thyroxine (L-T4), D-thyroxine (D-T4), 3,3', 5,5'-tetraio

144 triiodothyronine was detected, although the thyroxine level decreased in patients receiving eprotiro

145 in 1976 was inversely associated with total thyroxine level in 1996 but not in 2008.

146 range, 4.8-7.3 mU/L) and the mean (SD) free thyroxine level was 1.14 (0.16) ng/dL.

147 pin level, 4.60 to 19.99 mIU per liter; free thyroxine level within the reference range).

148 metabolic rate, body temperature, and serum thyroxine level.

149 ontrols, the knock-outs had markedly reduced thyroxine levels ( approximately 50-80%) and profoundly

150 ncreased in a linear manner with higher free thyroxine levels (hazard ratio, 2.41; confidence interva

151 Thyroxine levels and urinary free cortisol levels were p

152 are hypothyroid, and normalization of serum thyroxine levels does not reduce TEC H/P.

153 outside the reference range with normal free thyroxine levels in asymptomatic patients, is associated

154 of C2GnT3 altered behavior linked to reduced thyroxine levels in circulation.

155 Free thyroxine levels in middle-aged and elderly subjects wer

156 vated free triiodothyronine and lowered free thyroxine levels in the blood.

157 y cultured thyroid cells and increased serum thyroxine levels in TSH-suppressed rats in vivo.

158 Serum free thyroxine levels may be below the reference range (overt

159 Moreover, intrathyroid thyroxine levels of Slc30a10 single knockouts were lower

160 Higher free thyroxine levels were associated with lower cumulative n

161 inished weight gain and reduced plasma total thyroxine levels were found in both groups compared with

162 Free thyroxine levels were positively associated with high co

163 prid increased in the spleen, fawn survival, thyroxine levels, jawbone lengths, body weight, and orga

164 rmone, thyroid-stimulating hormone, and free thyroxine levels.

165 , may have enduring impacts on women's total thyroxine levels.

166 H <0.45 mIU/L, the last two with normal free thyroxine levels.

167 who have abnormal TSH levels and normal free thyroxine levels.

168 Maternal hypothyroxinemia (free thyroxine </=10th percentile, normal thyroid-stimulating

169 improved similarly between those receiving L-thyroxine (mean within-group change, -12.3 [95% CI, -16.

170 were also similar between those receiving L-thyroxine (mean within-group change, -8.9 [CI, -14.5 to

171 bulin (mean: +20.1%; 95% CI: 9.0, 32.2%) and thyroxine (mean: +1.5%; 95% CI: 0.0, 3.0%) increased per

172 Thyroxine modifies expressions of KSPG synthesis and car

173 uggests mechanisms for the inadequacies of l-thyroxine monotherapy and highlights the possible role f

174 Thereafter, l-thyroxine monotherapy at doses to normalize the serum TS

175 The last sentence of the section titled "L-Thyroxine Monotherapy Fails to Restore All Markers of Hy

176 has brought into question the inability of l-thyroxine monotherapy to universally normalize serum T3

177 on provided a physiologic means to justify l-thyroxine monotherapy, obviating concerns about inconsis

178 oxyacetamide, or oxoacetamide derivatives of thyroxine or deiodinated thyroxine.

179 L-thyroxine or matching placebo with mock dose titration.

180 Binding of the natural ligands thyroxine or retinol-binding protein (RBP) by Ser52Pro v

181 tabilizer of TTR in vitro that occupies both thyroxine pockets and the intramolecular channel between

182 significant competition for resveratrol and thyroxine preferential binding sites and lacked the abil

183 ons of polyphenols with both resveratrol and thyroxine preferential binding sites, by using resveratr

184 by elevated thyroid manganese, which blocks thyroxine production.

185 variate analysis, age, treatment group, free thyroxine, protein, and magnesium levels were associated

186 When thyroxine recipients were excluded, the HRs for particip

187 idism that must be treated with aggressive L-thyroxine replacement and other supportive measures in t

188 Thyroxine replacement therapy is highly effective and sa

189 ies formed between tetrameric transthyretin, thyroxine, retinol-binding protein, and retinol.

190 d the selection of conditions for removal of thyroxine's free fraction from samples without significa

191 Thyrotropin and free thyroxine should be measured and, when the latter is nor

192 tion factor A (TFAM) protein expression, and thyroxine stimulated complex II/IV activity.

193 ypothyroidism was defined by an above normal thyroxine-stimulating hormone concentration or by the ne

194 products" like the synthetic thyroid hormone thyroxine, strict regulations enforce a detailed chemica

195 he applied therapy, combined with adequate L-thyroxine substitution, as well as vitamin D and seleniu

196 but those treated with replacement doses of thyroxine survived more than 8 weeks.

197 ized interaction between the thyroid hormone thyroxine (T(4)) and the proinflammatory cytokine macrop

198 on of the contrast agent were collected, and thyroxine (T(4)) and thyroid-stimulating hormone (TSH) l

199 The thyroid hormones thyroxine (T(4)) and triiodothyronine (T(3)) play key ro

200 emical thyroidectomy on the one hand, and by thyroxine (T(4)) and triiodothyronine (T(3)) replacement

201 ear thyroid hormone receptor TRbeta1 (TR), L-thyroxine (T(4)) causes activation and nuclear transloca

202 transiently tetramerized by the locally high thyroxine (T(4)) concentration, chaperoning it out into

203 al thyroidectomy or after discontinuation of thyroxine (T(4)) in patients with thyroid cancer.

204 Thyroxine (T(4)) is the predominant form of thyroid horm

205 pening of a cryptic pocket that accommodates thyroxine (T(4)) through an I Se halogen bond to Sec170

206 at catalyze the conversion of the prohormone thyroxine (T(4)) to the active form of thyroid hormone,

207 ect of NT69L on blood glucose, cortisol, and thyroxine (T(4)) were all back to control levels after f

208 sitive method for the analysis of six THs, l-thyroxine (T(4)), 3,3',5-triiodo-l-thyronine (T(3)), 3,3

209 id-stimulating hormone (TSH), free and total thyroxine (T(4)), and total reverse T(3) from baseline t

210 Thyroid-stimulating hormone (TSH), free thyroxine (T(4)), free triiodothyronine (T(3)), and lept

211 ples for measurement of thyrotropin and free thyroxine (T(4)).

212 um concentration of the thyroid hormone (TH) thyroxine (T(4)).

213 onine) with high affinity, and its precursor thyroxine (T(4), 3,5,3',5'-tetraiodo-l-thyronine) with l

214 ion of thyroid hormones triiodothyronine and thyroxine (T3/T4) can impact metabolism, body compositio

215 Serum thyroxine, T3, and thyroid-stimulating hormone (TSH) lev

216 3,5,3'-triiodothyronine (T3) and high serum thyroxine/T3 (T4/T3) ratio.

217 HFs whether TRH (30 nM), TSH (10 mU ml(-1)), thyroxine (T4) (100 nM), and triiodothyronine (T3) (100

218 sociated with a 2.6-mug/dL decrease in total thyroxine (T4) (95% CI: -4.7, -0.35).

219 asing log10 perchlorate and decreasing total thyroxine (T4) [regression coefficient (beta) = -0.70; 9

220 selenoenzyme that activates the pro-hormone thyroxine (T4) and supplies most of the 3,5,3'-triiodoth

221 luorododecanoic acid (PFDoDA) had lower free thyroxine (T4) and total T4 levels.

222 tion, circulating levels of thyroid hormones thyroxine (T4) and triiodothyronine (T3) averaged 46.9 a

223 yroid, or thyroglobulin), which contain both thyroxine (T4) and triiodothyronine (T3), were the first

224 Serum triiodothyronine (T3) and thyroxine (T4) concentrations were slightly elevated com

225 at can compete with the thyroid hormone (TH) thyroxine (T4) for binding to transthyretin (TTR).

226 The displacement of l-thyroxine (T4) from binding sites on transthyretin (TTR)

227 e thyroid hormones triiodothyronine (T3) and thyroxine (T4) in aquatic wildlife exists despite the fa

228 and other tissues, capable of lowering serum thyroxine (T4) in rats.

229 Thyroxine (T4) injected in ovo on E9 induces precocious

230 4.00 mU or more per liter and a normal free thyroxine (T4) level (0.86 to 1.90 ng per deciliter [11

231 boxylate transporter 8 (MCT8) have low serum thyroxine (T4) levels that cannot be fully explained by

232 m 3,5,3'-triiodothyronine (T3) with normal l-thyroxine (T4) levels, is associated with malignancy.

233 We administered vehicle, thyroxine (T4) or metformin to neonatal rats post FAE an

234 hormones leptin, triiodothyrionine (T3), and thyroxine (T4) remain uncertain.

235 evidence suggests that the thyroid hormone L-thyroxine (T4) stimulates growth of cancer cells via a p

236 concentrations, either through inhibition of thyroxine (T4) synthesis or through inhibition of Dio me

237 es the type 2 deiodinase (D2) that activates thyroxine (T4) to 3,3',5-triiodothyronine (T3), the disr

238 elenoenzymes that catalyze the conversion of thyroxine (T4) to 3,5,3'-triiodothyronine (T3) and 3,3',

239 oidism involves the endogenous conversion of thyroxine (T4) to 3,5,3'-triiodothyronine (T3) and may n

240 (D2) activates thyroid hormone by converting thyroxine (T4) to 3,5,3'-triiodothyronine (T3).

241 perthyroidism was generated by addition of L-thyroxine (T4) to drinking water.

242 o2a and dio2b, responsible for conversion of thyroxine (T4) to T3.

243 pe II iodothyronine deiodinase (D2) converts thyroxine (T4) to the active hormone 3,5,3'-triiodothyro

244 pe 2 deiodinase (D2) converts the prohormone thyroxine (T4) to the metabolically active molecule 3,5,

245 zymes, such as TH deiodinases, which convert thyroxine (T4) to the physiologically active TH, triiodo

246 DIO2 converts thyroxine (T4) to triiodothyronine (T3), which binds to

247 Serum TSH and free thyroxine (T4) were measured.

248 thyroid hormones (triiodothyronine (T3) and thyroxine (T4)), thyroid-stimulating hormone, thyroid pe

249 The thyroid hormones triiodothyronine (T3), thyroxine (T4), and thyrotropin (TSH) were measured in p

250 e examined through thyroid histology, plasma thyroxine (T4), and triiodothyronine (T3), and hepatic o

251 f the label by the natural thyroid hormone l-thyroxine (T4), as a model analyte, is demonstrated in w

252 Serum insulin, thyroxine (T4), corticosterone, and adipokines were meas

253 oped for the analysis of the thyroid hormone thyroxine (T4), inflammation biomarker C-reactive protei

254 Rats received placebo, 3.3-mg l-thyroxine (T4), or 20-mg T4 pellets (60-day release form

255 We also measured free thyroxine (T4), total T4, and thyroid-stimulating hormon

256 The thyroid gland synthesizes thyroxine (T4), which passes through the larval tadpole'

257 1 induced a dose-dependent increase in serum thyroxine (T4), with a maximum effect after 10 proportio

258 Precocious thyroxine (T4)-induced increases in corneal thinning/tra

259 The TTR-binding activity was measured as thyroxine (T4)-like equivalents (T4-EQMeas).

260 ced to undergo metamorphosis via exposure to thyroxine (T4).

261 r levels of triiodothyronine (T3) and higher thyroxine (T4).

262 phytohaemagglutinin skin test, p < 0.0001), thyroxine (T4, p = 0.042), and glutathione (GSH, p = 0.0

263 eled T3 internal standard (T3-13C9), labeled thyroxine (T4-d5) is also added to serum samples in orde

264 ing vessels was increased 3-fold by either l-thyroxine (T4; 10(-7) mol/L) or 3,5,3'-triiodo-l-thyroni

265 membrane receptor, binds thyroid hormones (L-thyroxine, T4; 3,5,3'-triiodo-L-thyronine, T3) and is ov

266 Thyroxine (tetraiodothyronine [T4]), T3, and TSH levels

267 l compartment to a hypertrophic regimen with thyroxine, the cartilage discs underwent progressive dee

268 e 2 deiodinase (D2), an enzyme that converts thyroxine, the main form of thyroid hormone in the circu

269 In 10 patients receiving thyroxine, the mean retention of diagnostic (131)I after

270 mmune thyroiditis, of whom 56 were receiving thyroxine therapy.

271 of hypothyroidism, 11 of whom were receiving thyroxine therapy.

272 urrently reads "... for steady delivery of L-thyroxine").This has been corrected in the online versio

273 al thyroid hormone levels (thyrotropin, free thyroxine, thyroid peroxidase antibodies) were measured

274 time of 90 ms and allowed the amount of free thyroxine to be determined within 30 s after sample inje

275 thelial cell line, HLE B-3, was treated with thyroxine to determine whether this treatment increases

276 eiodinase (D2) that activates the prohormone thyroxine to the active hormone triiodothyronine, modify

277 activation by accelerating the conversion of thyroxine to triiodothyronine via type 2 deiodinase in m

278 ones (ie, thyroid-stimulating hormone, total thyroxine, total triiodothyronine, free thyroxine, free

279 The tetrameric thyroxine transport protein transthyretin (TTR) forms am

280 Transthyretin (TTR) is a thyroxine-transport protein found in the blood that has

281 ays of growth in a hyperoxic atmosphere, the thyroxine-treated cells were 20 times more viable than w

282 in the amount of lipid oxidation products in thyroxine-treated cells.

283 Thyroxine treatment alleviates hormone resistance in pat

284 A 100% increase in cardiolipin with thyroxine treatment may contribute to a decrease in reac

285 in REE after a clinical intervention (e.g., thyroxine treatment of RTHalpha) to be monitored.

286 Thyroxine treatment reduced the amount of lipid oxidatio

287 As a result of thyroxine treatment, the phosphatidylcholine (PC)-to-sph

288 including thyroid-stimulating hormone (TSH), thyroxine, triiodothyronine resin uptake, and free thyro

289 compensate for thyroid dysfunction, as serum thyroxine/triiodothyronine and somatic growth were norma

290 zo-p-dioxins and furans, with THs [total (L)-thyroxine (TT(4)), total 3,3',5-triiodo-(L)-thyronine (T

291 d a 53% and 46% decline in circulating total thyroxine (TT4) and 3,5,3'-triiodothyronine (TT3), respe

292 of thyroid-stimulating hormone (TSH), total thyroxine (TT4), and PFAAs were measured during 2005-200

293 (FT4), whereas TDCIPP also influenced total thyroxine (TT4).

294 ips between thyroid hormones (total and free thyroxine [TT4 and FT4], total and free triiodothyronine

295 or Tiredness score modified the effects of L-thyroxine versus placebo (P for interaction = 0.20 and 0

296 Binding of the natural ligand thyroxine was clearly observed, and a range of small mol

297 imulating hormone, total thyroxine, and free thyroxine, were measured in serum samples collected betw

298 of the thyroid hormones triiodothyronine and thyroxine, which are required for the development of the

299 hypothyroidism is replacement with synthetic thyroxine, which undergoes peripheral conversion to trii

300 ions of thyroid-stimulating hormone and free thyroxine with the outcomes were assessed through logist